SCHEMBL7084833

SCHEMBL7084833

COc1ccc(C(=O)Nc2ccc(C(=O)C[N+](=O)[O-])c(Cl)c2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TNKS O95271 1/20 0.52
TNKS2 Q9H2K2 1/20 0.52
NPC1 O15118 8/20 0.52
RAB9A P51151 7/20 0.52
SMN1; SMN2 Q16637 6/20 0.52
TP53 P04637 4/20 0.52
ALOX15 P16050 1/20 0.52
CHRM1 P11229 1/20 0.52
ALDH1A1 P00352 6/20 0.51
ALOX5 P09917 1/20 0.51
TAS1R3 Q7RTX0 1/20 0.50
TAS1R1 Q7RTX1 1/20 0.50
TAS1R2 Q8TE23 1/20 0.50
GAA P10253 2/20 0.49
MAPK1 P28482 1/20 0.49
HTT P42858 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49
KMT2A Q03164 3/20 0.49
MEN1 O00255 2/20 0.49
CYP1A2 P05177 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7088685 0.87 CHRM2 (0.49) NPC1RAB9ASMN1; SMN2TP53CHRM1
SCHEMBL7091413 0.87 NPC1 (0.48) NPC1RAB9ASMN1; SMN2TP53ALDH1A1
SCHEMBL7088400 0.85 NPC1 (0.58) NPC1RAB9ATP53CHRM1KMT2A
SCHEMBL7088352 0.85 SMN1; SMN2 (0.52) RAB9ASMN1; SMN2ALDH1A1NPSR1KMT2A
SCHEMBL7089035 0.82 MAPK1 (0.51) NPC1RAB9ASMN1; SMN2ALDH1A1GAA
SCHEMBL7089037 0.80 KMT2A (0.55) SMN1; SMN2ALDH1A1GAAHTTKMT2A
SCHEMBL3787237 0.76 MAPT (0.68) NPC1RAB9ASMN1; SMN2TP53ALOX15
SCHEMBL7085114 0.76 MAPT (0.53) NPC1RAB9ASMN1; SMN2ALDH1A1GAA
SCHEMBL7085764 0.74 TGM2 (0.49) RAB9ASMN1; SMN2KMT2AMAPTLMNA
SCHEMBL8211752 0.74 RAB9A (0.45) NPC1RAB9ASMN1; SMN2ALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030171422-A1 New nitromethyl ketones, process for preparing them and compositions containing them MERCK PATENT GMBH (DE) 2003-09-11 US disclosed
US-6559185-B2 Nitromethyl ketone compounds having aldose reduction inhibiting properties and methods for their use MERCK PATENT GMBH (DE) 2003-05-06 US disclosed
US-20030069312-A1 Antidiabetic agents LARDY CLAUDE (FR) 2003-04-10 US disclosed
US-6043281-A ALDOSE REDUCTASE INHIBITORS; TREATMENT OR PREVENTION OF COMPLICATIONS OF DIABETES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2000-03-28 US disclosed
EP-0983226-A1 NEW NITROMETHYL KETONES, PROCESS FOR PREPARING THEM AND COMPOSITIONS CONTAINING THEM MERCK PATENT GmbH (DE) 2000-03-08 EP disclosed
US-5932765-A REDUCTASE INHIBITORS MERCK PATENT GESELLSCHAFT MIT (DE) 1999-08-03 US disclosed
WO-1998052906-A1 NEW NITROMETHYL KETONES, PROCESS FOR PREPARING THEM AND COMPOSITIONS CONTAINING THEM MERCK PATENT GMBH (DE) 1998-11-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069312-A1 Antidiabetic agents SLC5A1, SLC5A2, GPR119 TNKS 3474/4885TNKS2 3816/4885NPC1 660/4885
US-20030171422-A1 New nitromethyl ketones, process for preparing them and compositions containing them AKR1B1, AKR1A1, AKR1C1 TNKS 922/4885TNKS2 1460/4885NPC1 855/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.